Kulkarni Samarth

Chief Executive Officer

Kulkarni Samarth has filed 9 SEC Form 4 filings (17 transaction rows) across 1 company, with disclosures dating back to 2025. 9 of those filings fall inside the rolling window. Most recent filing: Mar 24, 2026.

On the most recent filing, Kulkarni Samarth is listed as Chief Executive Officer at CRISPR Therapeutics AG. Inside the rolling window, Kulkarni Samarth reported no open-market purchases and 8 open-market sales totaling $10.8M in CRSP. The largest disclosed transaction in the window is a sale of 60,000 CRSP shares on Jan 22, 2026, worth $3.6M.

Companies traded

Other insiders at CRSP

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$10.8M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
CRSPSale$469KMar 24SEC ↗
CRSPSale$499KMar 17SEC ↗
CRSPSale$517KMar 12SEC ↗
CRSPSale$366KFeb 20SEC ↗
CRSPSale$1.6MJan 22SEC ↗
CRSPSale$3.6MJan 22SEC ↗
CRSPSale$3.5MOct 20SEC ↗
CRSPSale$283KOct 15SEC ↗
Showing 1–8 of 8
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Kulkarni Samarth made?

Kulkarni Samarth has filed 9 SEC Form 4 filings (17 transaction rows) across 1 company since 2025.

Which companies does Kulkarni Samarth trade?

Kulkarni Samarth has filed SEC Form 4 disclosures for 1 company, including CRSP.

When was Kulkarni Samarth's most recent SEC Form 4 filing?

Kulkarni Samarth's most recent SEC Form 4 filing on Tracefour is dated Mar 24, 2026.

What is Kulkarni Samarth's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Kulkarni Samarth is listed as Chief Executive Officer.

What is Kulkarni Samarth's total buy and sell value in the current window?

Inside the rolling retention window, Kulkarni Samarth bought $0 and sold $10.8M based on SEC Form 4 filings.

What was Kulkarni Samarth's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 60,000 CRSP shares on 2026-01-22, worth $3.6M, per SEC Form 4 filings.